Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors

Author(s): S. Schenone, C. Brullo, F. Musumeci, M. Biava, F. Falchi and M. Botta

Volume 18, Issue 19, 2011

Page: [2921 - 2942] Pages: 22

DOI: 10.2174/092986711796150531

Price: $65

Abstract

Fyn is a non-receptor tyrosine kinase belonging to the Src family kinases. It has been shown to play important roles in neuronal functions, including myelination and oligodendrocytes formation, and in inflammatory processes. It has also demonstrated its involvement in signaling pathways that lead to severe brain pathologies, such as Alzheimers and Parkinsons diseases. Moreover, Fyn is upregulated in some malignancies. Experimental studies demonstrated that Fyn inhibition could be useful in the disruption of metabolic processes involved in cancer and in neurodegenerative diseases. Unfortunately no specific Fyn inhibitor has been discovered so far, being the reported compounds active also on other members of Src family or on different tyrosine kinases. However, multitargeted inhibitors might be endowed with therapeutic potential. Indeed, as increasingly reported, also a not completely selective inhibitor of a specific protein could be therapeutically useful, affecting a number of cell pathways involved especially in cancer development. In this review, we report some examples of small molecule tyrosine kinase inhibitors for which data on Fyn inhibition, both in enzymatic and in cell assays, have been reported, with the aim of giving information as starting point for the researchers working in this field.

Keywords: Fyn, Src, tyrosine kinase, Alzheimer's disease, brain, cancer, inhibitors


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy